CorMedix Inc.
CorMedix Inc. (CRMD): 5 pipeline candidates · 3 upcoming catalysts · ~17 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
17.4 months
D/E 0.87 · 19% dilution
Lead: Approved
5 candidates
3 upcoming, next in ~562d
0 buys · 2 sells (180d)
A transparent, data-derived signal for CorMedix Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$680.9M
Cash
$179.1M
Quarterly Burn
$41.5M
Runway
17.4 mo
Revenue
$127.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| catheter lock | Phase 3 |
| DefenCath | Phase 4 |
| Neutrolin | Approved |
| rezzayo | Phase 3 |
| taurolidine (for neuroblastoma in children) | Preclinical |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
189
Total value held
$307.7M
| Holder | Shares | Value |
|---|---|---|
| deep track capital, lp | 6,274,076 | $42.6M |
| vanguard capital management llc | 6,259,312 | $42.5M |
| blackrock, inc. | 5,967,575 | $40.5M |
| state street corp | 2,191,843 | $14.9M |
| susquehanna international group, llp | 1,894,810 | $12.9M |
| royce & associates lp | 1,887,532 | $12.8M |
| geode capital management, llc | 1,816,907 | $12.3M |
| oberweis asset management inc/ | 1,211,115 | $8.2M |
| alyeska investment group, l.p. | 850,000 | $5.8M |
| vanguard portfolio management llc | 742,571 | $5.0M |
Showing top 10 of 189 institutional holders of CorMedix Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CorMedix Inc.'s pipeline?
CorMedix Inc. (CRMD) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CorMedix Inc.'s lead drug candidate?
CorMedix Inc.'s most advanced tracked candidate is catheter lock (Phase 3) for Central Line Associated Blood Stream Infections (CLABSI); Catheter-Related Infections.
What is CorMedix Inc.'s next catalyst?
CorMedix Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonst" — expected January 1, 2028.
What is CorMedix Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CorMedix Inc. has approximately 17.4 months of cash runway.
What is CorMedix Inc.'s market capitalization?
CorMedix Inc.'s market capitalization is approximately $680.9M.
Get the full picture on CorMedix Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.